Korea Investment Accelerator
DAYLI Patners
NEXT-SCN
World-first multimodal platform that measures in-vivo synaptic integrity to objectively verify the impact of synapse-targeted therapies.
NEXT-STAGE
MRI in, tau insight out. NEXT‑STAGE infers regional tau burden from routine MRI noninvasive, scalable, and cost‑effective. PET‑complementary, built for research teams in biopharma and academic hospitals.